WebRLY-4008 for Bile Duct Cancer. Phase-Based Progress Estimates. 1. Effectiveness. 1. Safety. Texas Oncology, Dallas, TX Bile Duct Cancer + 12 More RLY-4008 - Drug. You have a chance of qualifying for this trial. We made sure your application will take less than 5 … WebNov 23, 2024 · RLY-4008, a highly selective FGFR2 inhibitor, has demonstrated promising efficacy in patients with FGFR2 -altered cholangiocarcinoma, while sparing patients the …
ESMO Congress OncologyPRO
Web• RLY-4008 is a novel potent and highly selective FGFR2 inhibitor designed to overcome the emergence of on-target FGFR2 resistance mutations and dose-limiting toxicities associated with current pan-FGFR inhibitors. • RLY-4008 is > 200-fold selective over FGFR1, and > 80- and > 5000-fold selective over FGFR3 and FGFR4, respectively. WebApr 2, 2024 · Vice President, Medical Leader – Late Development Oncology (RLY-4008) at Relay Therapeutics Relay Therapeutics is seeking a motivated and patient-centric VP, Late Development Medical Leader who is looking to have a broad and tangible impact on small molecule drug development. Reporting into the SVP, Head of Clinical Development, … led kitchen under cupboard lights
RLY-4008 for Bile Duct Cancer Clinical Trial 2024 Power
WebSep 11, 2024 · A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial (NCT04526106) presented at the 2024 ESMO Congress.. Preliminary data showed that … WebApr 12, 2024 · The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibit... WebDec 1, 2024 · RLY-4008 is a highly selective and potent oral inhibitor designed to target both FGFR2 driver and resistance mutations. We initiated a first-in-human study in advanced … led knauf